Chronic kidney disease (CKD) is a common1 yet widely underrecognized and potentially deadly condition2,3 and is estimated to affect more than 160 million people with type 2 diabetes (T2D) worldwide.4,5,6 CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced.7,8
In addition, patients with CKD and T2D are approximately three times more likely to die from a cardiovascular (CV)-related cause than those with T2D alone.9
Hear from leading experts below on how outcomes can be improved for patients living with CKD and T2D, alongside insights from their experience and best practices.
Professor Peter Rossing
Head of Complications Research at Steno Diabetes Center Copenhagen, Denmark
Professor Carolyn Lam
Senior Consultant of the National Heart Centre, Singapore
Primary Care Physician
Professor Richard Hobbs
Nuffield Professor of Primary Care Health Sciences, UK
Professor Christoph Wanner
Professor of Medicine and Head of the Division of Nephrology University Hospital of Würzburg, Germany
The risk of CV events such as myocardial infarction or hospitalisation for heart failure appears early in the course of CKD in T2D, and grows with disease severity10 – leading to an increased risk of experiencing a fatal CV event. Learn why cardiovascular management should be considered for patients with CKD and T2D as early as possible.
A panel discussion on chronic kidney disease in T2D with four key opinion leaders.
The panel discusses what comprises a collaborative approach for patients with CKD in T2D that need multidisciplinary care.
The panel discusses the type of tests and the testing protocols that are involved in diagnosing CKD early.
The panel discusses the key challenges when clinicians discuss kidney health with patients with CKD and T2D.
The panel discusses the different roles of health care providers to support the management of patients with CKD and T2D as a broader team.